News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,173 Results
Type
Article (41399)
Company Profile (297)
Press Release (684466)
Multimedia
Podcasts (90)
Webinars (17)
Section
Business (205629)
Career Advice (2039)
Deals (35660)
Drug Delivery (116)
Drug Development (81605)
Employer Resources (173)
FDA (16458)
Job Trends (15006)
News (347758)
Policy (32849)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2591)
Accelerated approval (37)
Adcomms (24)
Allergies (149)
Alliances (49922)
ALS (176)
Alzheimer's disease (1689)
Antibody-drug conjugate (ADC) (329)
Approvals (16736)
Artificial intelligence (542)
Autoimmune disease (165)
Automation (44)
Bankruptcy (364)
Best Places to Work (11658)
BIOSECURE Act (21)
Biosimilars (195)
Biotechnology (190)
Bladder cancer (165)
Brain cancer (58)
Breast cancer (651)
Cancer (4965)
Cardiovascular disease (410)
Career advice (1724)
Career pathing (37)
CAR-T (288)
CDC (50)
Celiac Disease (2)
Cell therapy (766)
Cervical cancer (37)
Clinical research (69866)
Collaboration (1774)
Company closure (4)
Compensation (1184)
Complete response letters (58)
COVID-19 (2732)
CRISPR (96)
C-suite (890)
Cystic fibrosis (145)
Data (6433)
Decentralized trials (2)
Denatured (30)
Depression (138)
Diabetes (511)
Diagnostics (6760)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (265)
Drug pricing (190)
Drug shortages (28)
Duchenne muscular dystrophy (239)
Earnings (90611)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (118201)
Executive appointments (999)
FDA (19662)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1521)
Gene editing (207)
Generative AI (44)
Gene therapy (617)
GLP-1 (983)
Government (4691)
Grass and pollen (6)
Guidances (385)
Healthcare (18908)
HIV (68)
Huntington's disease (48)
IgA nephropathy (84)
Immunology and inflammation (262)
Immuno-oncology (67)
Indications (127)
Infectious disease (3020)
Inflammatory bowel disease (200)
Inflation Reduction Act (16)
Influenza (124)
Intellectual property (258)
Interviews (316)
IPO (16678)
IRA (52)
Job creations (3678)
Job search strategy (1440)
JPM (57)
Kidney cancer (18)
Labor market (87)
Layoffs (557)
Leadership (33)
Legal (7987)
Liver cancer (92)
Longevity (17)
Lung cancer (669)
Lymphoma (384)
Machine learning (45)
Management (59)
Manufacturing (828)
MASH (166)
Medical device (13804)
Medtech (13864)
Mergers & acquisitions (20068)
Metabolic disorders (1297)
mRNA (161)
Multiple sclerosis (166)
NASH (16)
Neurodegenerative disease (333)
Neuropsychiatric disorders (90)
Neuroscience (2967)
Neurotech (1)
NextGen: Class of 2026 (6556)
Non-profit (4527)
Now hiring (69)
Obesity (610)
Opinion (270)
Ovarian cancer (169)
Pain (206)
Pancreatic cancer (240)
Parkinson's disease (291)
Partnered (35)
Patents (516)
Patient recruitment (521)
Peanut (59)
People (59321)
Pharmaceutical (66)
Pharmacy benefit managers (30)
Phase 1 (21800)
Phase 2 (30750)
Phase 3 (22902)
Pipeline (5773)
Policy (296)
Postmarket research (2565)
Preclinical (9251)
Press Release (64)
Prostate cancer (253)
Psychedelics (48)
Radiopharmaceuticals (289)
Rare diseases (885)
Real estate (6002)
Recruiting (70)
Regulatory (24704)
Reports (53)
Research institute (2402)
Resumes & cover letters (354)
Rett syndrome (29)
RNA editing (19)
RSV (81)
Schizophrenia (150)
Series A (257)
Series B (194)
Service/supplier (13)
Sickle cell disease (101)
Special edition (22)
Spinal muscular atrophy (158)
Sponsored (42)
Startups (3673)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (58)
Vaccines (1024)
Venture capital (91)
Weight loss (392)
Women's health (98)
Worklife (19)
Date
Today (3)
Last 7 days (878)
Last 30 days (2704)
Last 365 days (29988)
2026 (4883)
2025 (30329)
2024 (35328)
2023 (40178)
2022 (51288)
2021 (55834)
2020 (54153)
2019 (46641)
2018 (35123)
2017 (32221)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27525)
Location
Africa (740)
Alabama (86)
Alaska (7)
Arizona (315)
Arkansas (13)
Asia (39487)
Australia (6471)
California (11668)
Canada (3357)
China (1123)
Colorado (490)
Connecticut (489)
Delaware (342)
Europe (85261)
Florida (1746)
Georgia (370)
Hawaii (3)
Idaho (62)
Illinois (889)
India (71)
Indiana (538)
Iowa (22)
Japan (442)
Kansas (128)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1415)
Massachusetts (8322)
Michigan (335)
Minnesota (637)
Mississippi (6)
Missouri (129)
Montana (32)
Nebraska (29)
Nevada (125)
New Hampshire (81)
New Jersey (3086)
New Mexico (28)
New York (3055)
North Carolina (1484)
North Dakota (8)
Northern California (5729)
Ohio (348)
Oklahoma (21)
Oregon (42)
Pennsylvania (2344)
Puerto Rico (24)
Rhode Island (49)
South America (1111)
South Carolina (68)
South Dakota (1)
Southern California (4548)
Tennessee (180)
Texas (1797)
United States (41210)
Utah (350)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (942)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
726,173 Results for "neurocrine biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
December 23, 2025
·
2 min read
·
Nick Paul Taylor
Rare diseases
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.
January 7, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
January 27, 2026
·
5 min read
Press Releases
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
January 22, 2026
·
2 min read
Press Releases
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
February 12, 2026
·
18 min read
Press Releases
Neurocrine Biosciences to Host R&D Day on December 16
December 10, 2025
·
1 min read
Press Releases
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
Press Releases
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
December 23, 2025
·
6 min read
Press Releases
Neurocrine Biosciences to Present at Upcoming Investor Conferences - November 11, 2025
November 11, 2025
·
1 min read
Press Releases
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
October 28, 2025
·
17 min read
1 of 72,618
Next
